JP2019516737A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516737A5
JP2019516737A5 JP2018560884A JP2018560884A JP2019516737A5 JP 2019516737 A5 JP2019516737 A5 JP 2019516737A5 JP 2018560884 A JP2018560884 A JP 2018560884A JP 2018560884 A JP2018560884 A JP 2018560884A JP 2019516737 A5 JP2019516737 A5 JP 2019516737A5
Authority
JP
Japan
Prior art keywords
methyl
amino
benzenesulfonamide
thiazol
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516737A (ja
JP6938545B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/033634 external-priority patent/WO2017201468A1/en
Publication of JP2019516737A publication Critical patent/JP2019516737A/ja
Publication of JP2019516737A5 publication Critical patent/JP2019516737A5/ja
Priority to JP2021142186A priority Critical patent/JP2021185189A/ja
Application granted granted Critical
Publication of JP6938545B2 publication Critical patent/JP6938545B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560884A 2016-05-20 2017-05-19 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 Active JP6938545B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021142186A JP2021185189A (ja) 2016-05-20 2021-09-01 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662339773P 2016-05-20 2016-05-20
US62/339,773 2016-05-20
US201662432152P 2016-12-09 2016-12-09
US62/432,152 2016-12-09
PCT/US2017/033634 WO2017201468A1 (en) 2016-05-20 2017-05-19 Benzenesulfonamide compounds and their use as therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021142186A Division JP2021185189A (ja) 2016-05-20 2021-09-01 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用

Publications (3)

Publication Number Publication Date
JP2019516737A JP2019516737A (ja) 2019-06-20
JP2019516737A5 true JP2019516737A5 (https=) 2020-06-25
JP6938545B2 JP6938545B2 (ja) 2021-09-22

Family

ID=58794232

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018560884A Active JP6938545B2 (ja) 2016-05-20 2017-05-19 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
JP2021142186A Withdrawn JP2021185189A (ja) 2016-05-20 2021-09-01 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
JP2023099277A Withdrawn JP2023108032A (ja) 2016-05-20 2023-06-16 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
JP2025068729A Pending JP2025105687A (ja) 2016-05-20 2025-04-18 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021142186A Withdrawn JP2021185189A (ja) 2016-05-20 2021-09-01 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
JP2023099277A Withdrawn JP2023108032A (ja) 2016-05-20 2023-06-16 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
JP2025068729A Pending JP2025105687A (ja) 2016-05-20 2025-04-18 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用

Country Status (23)

Country Link
US (4) US10246453B2 (https=)
EP (1) EP3458449B1 (https=)
JP (4) JP6938545B2 (https=)
KR (1) KR102366077B1 (https=)
CN (1) CN109526219B (https=)
AU (2) AU2017268006B2 (https=)
CA (1) CA3023465C (https=)
CL (1) CL2018003260A1 (https=)
CO (1) CO2018012485A2 (https=)
ES (1) ES3022639T3 (https=)
HR (1) HRP20250505T1 (https=)
HU (1) HUE071358T2 (https=)
IL (1) IL262834B (https=)
MX (1) MX386471B (https=)
MY (1) MY199208A (https=)
PH (1) PH12018502378B1 (https=)
PL (1) PL3458449T3 (https=)
RS (1) RS66796B1 (https=)
RU (1) RU2769827C2 (https=)
SG (2) SG10201912216VA (https=)
TN (1) TN2018000385A1 (https=)
WO (1) WO2017201468A1 (https=)
ZA (1) ZA201807518B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250505T1 (hr) * 2016-05-20 2025-06-20 Xenon Pharmaceuticals Inc. Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
ES2967410T3 (es) 2016-12-09 2024-04-30 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
CN112262142B (zh) 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
MA53488A (fr) * 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
AU2020388645B2 (en) * 2019-11-21 2026-03-19 University Of Utah Research Foundation TRPV4 receptor ligands
EP4228654A4 (en) * 2020-10-13 2024-10-16 Xenon Pharmaceuticals Inc. USE OF THE NAV1.6 SODIUM CHANNEL BLOCKER, (S)-4-((1-BENZYLPYRROLIDIN-3-YL))(METHYL) AMINO)-2-FLUORO-5-METHYL-N(THIAZOL-4-YL) BENZENESULFONAMIDE, IN CONJUNCTION WITH STRONG CYTOCHROME P450 3A4 INDUCERS, IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NAV1.6 ACTIVITY
WO2022077094A1 (en) * 2020-10-13 2022-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical formulations for treating diseases associated with voltage-gated sodium channels
US20250333404A1 (en) * 2022-06-02 2025-10-30 Neurocrine Biosciences, Inc. Deuterated compounds
CR20250551A (es) * 2023-07-07 2026-01-19 Novartis Ag Bloqueadores de canales de sodio
WO2025024795A1 (en) * 2023-07-27 2025-01-30 Neurocrine Biosciences, Inc. Crystalline forms
WO2025103409A1 (zh) * 2023-11-16 2025-05-22 南京同诺康医药科技有限公司 Nmt抑制剂及其制备方法和用途
PY24113579A (es) 2023-12-21 2025-07-30 Syngenta Crop Protection Ag Compuestos de quinazolina con actividad plaguicida

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
US6416780B1 (en) 1997-05-07 2002-07-09 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
ES2208364T3 (es) 1999-07-16 2004-06-16 Warner-Lambert Company Llc Procedimiento para tratar dolor cronico usando inhibidores de mek.
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1646628A1 (en) 2003-07-08 2006-04-19 Novartis AG Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
EP1673357A2 (en) 2003-08-08 2006-06-28 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
WO2006066109A2 (en) 2004-12-17 2006-06-22 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
EP1937658A1 (en) 2005-10-06 2008-07-02 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
EP2316829A1 (en) * 2005-12-21 2011-05-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2008019967A2 (en) 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
WO2009012241A1 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
KR20110027657A (ko) 2008-06-25 2011-03-16 다이이찌 산쿄 가부시키가이샤 카르복실산 화합물
WO2010002956A2 (en) 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
PE20120008A1 (es) 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
KR101541086B1 (ko) 2010-08-20 2015-08-03 허치슨 메디파르마 리미티드 피롤로피리미딘 화합물 및 그 용도
MX2014001851A (es) 2011-08-17 2014-10-24 Amgen Inc Inhibidores del canal de heteroarilo sodio.
IN2014CN02959A (https=) 2011-10-28 2015-07-03 Merck Sharp & Dohme
JP6014155B2 (ja) * 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US9630929B2 (en) * 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
SG11201408284VA (en) * 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
ES2798138T3 (es) 2012-10-15 2020-12-09 Dae Woong Pharma Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos
CA2889378A1 (en) 2012-10-26 2014-05-01 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
US9388179B2 (en) 2012-10-26 2016-07-12 Merck Sharp & Dohme Corp. N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
JP6407285B2 (ja) 2013-09-09 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company RORγ調節因子
AU2014318979B2 (en) 2013-09-10 2019-03-28 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
CR20160296A (es) * 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
JP6337124B2 (ja) 2013-12-23 2018-06-06 パーデュー、ファーマ、リミテッド、パートナーシップ インダゾール及びその使用
CN106715418A (zh) * 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
CN106795149B (zh) 2015-05-05 2019-09-24 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
EP3389654B1 (en) 2015-12-18 2023-08-16 Merck Sharp & Dohme LLC Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
HRP20250505T1 (hr) 2016-05-20 2025-06-20 Xenon Pharmaceuticals Inc. Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
US10968210B2 (en) 2016-11-17 2021-04-06 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
ES2967410T3 (es) 2016-12-09 2024-04-30 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
CN112262142B (zh) * 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques

Similar Documents

Publication Publication Date Title
JP2019516737A5 (https=)
RU2018145045A (ru) Соединения бензолсульфонамида и их применение в качестве терапевтических средств
JP2010533158A5 (https=)
JP5261383B2 (ja) ヒトプロテインチロシンホスファターゼ阻害剤および使用法
RU2005106844A (ru) [1,2,4]оксодиазолы (варианты), способ их получения, и фармацевтическая композиция и способ (варианты) ингибирования активации метаботропных глютаматных рецепторов-5
JP2006503009A5 (https=)
JP2020516671A5 (https=)
JP2015517580A5 (https=)
JP2004502670A5 (https=)
RU2009109147A (ru) Органические соединения
JP2021500345A5 (https=)
JP2018535999A5 (https=)
JP2009542659A5 (https=)
JP2007528887A5 (https=)
JP2005504058A5 (https=)
RU2017124425A (ru) Производные 2,4-диоксо-хиназолин-6-сульфонамида в качестве ингибиторов parg
JP2006506340A5 (https=)
JP2009525340A5 (https=)
JP2021535137A5 (https=)
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2007523208A5 (https=)
JP2013533868A5 (https=)
JP2006524686A5 (https=)
JP2010540462A5 (https=)
JP2021535134A5 (https=)